Edition:
United Kingdom

People: Akebia Therapeutics Inc (AKBA.OQ)

AKBA.OQ on NASDAQ Stock Exchange Global Market

4.57USD
18 Jun 2019
Change (% chg)

-- (--)
Prev Close
$4.57
Open
--
Day's High
--
Day's Low
--
Volume
--
Avg. Vol
339,695
52-wk High
$11.60
52-wk Low
$4.09

Dahan, Michel 

Mr. Michel Dahan serves as Senior Vice President and Chief Business Officer of the Company. Prior to joining Akebia, from 2010 to 2013, Mr. Dahan held various positions at Inspiration Biopharmaceuticals, Inc., a company that filed for protection under Chapter 11 of the U.S. Bankruptcy Code in October 2012 prior to the successful sale of its hemophilia assets to Cangene Corporation and Baxter International in early 2013, most recently as Vice President, Commercial Development and Strategic Planning, and led the global marketing and commercial development in preparation for two global launches. Prior to that, from 2003 to 2010, Mr. Dahan served in various roles for Ipsen, most recently as International Product Director, working on global marketing and strategic planning for their hemophilia franchise, and Strategic Planning Director. Previously, he was in Global Business Development and Licensing for Ipsen. He began his career at BNP Paribas in the investment banking division in 2002. He earned his graduate degree in business administration at HEC Paris (France), his maitrise in mathematics from University Paris VI (France) and completed his executive education program (PLD) at Harvard Business School.

Basic Compensation

Total Annual Compensation, USD 315,097
Restricted Stock Award, USD 400,530
Long-Term Incentive Plans, USD --
All Other, USD 561,161
Fiscal Year Total, USD 1,276,790

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --
Name Fiscal Year Total

John Butler

3,409,220

Jason Amello

869,218

Nicole Hadas

--

Michel Dahan

1,276,790

Dell Faulkingham

--

Rita Jain

2,241,720
As Of  31 Dec 2017